All In Biotech

NDA 022402 · Hikma

Codeine Sulfate

Codeine Sulfate · Oral

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jul 16, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

511

100 Phase 3, 26 recruiting

FAERS reports

3,309

2,121 serious, 799 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF CODEINE SULFATE TABLETS Addiction, Abuse, and Misuse Because the use of Codeine Sulfate Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.1 ), Dosage and Administration ( 2.1 )] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of Codeine Sulfate Tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Codeine Sulfate Tablets are essential [see Warnings and Precautions ( 5.2 )] . Accidental Ingestion Accidental ingestion of...

What it is approved for

From the label in effect Dec 22, 2025.

Codeine Sulfate Tablets are indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. Limitations of Use: • Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions ( 5.1 )] , reserve opioid analgesics, including Codeine Sulfate Tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Codeine Sulfate Tablets are an opioid agonist, indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. ( 1 ) Limitations of Use • Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including Codeine Sulfate Tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 )

Mechanism: Codeine sulfate is an opioid agonist relatively selective for the mu-opioid receptor, but with a much weaker affinity than morphine. The analgesic properties of codeine have been speculated to come from its conversion to morphine, although the exact mechanism of analgesic action remains unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • CODEINE SULFATE · CODEINE SULFATE 60MG · TABLET, ORAL · Prescription · TE AB
  • CODEINE SULFATE · CODEINE SULFATE 15MG · TABLET, ORAL · Prescription · TE AB
  • CODEINE SULFATE · CODEINE SULFATE 30MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Codeine" as an intervention, any sponsor and status, largest first.

All 511 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity817
  • nausea506
  • drug ineffective400
  • malaise380
  • vomiting373
  • headache371
  • arthralgia363
  • diarrhoea352
  • dyspnoea338
  • fatigue310
  • cough309
  • pain286

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
20051
20071
200921
2010233
2011387
2012501
2013154
2014232
2015102
2016122
2017144
2018156
2019243
2020154
2021120
2022200
2023140
2024201
2025131
202658

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Codeine Sulfate (Codeine Sulfate)

2024 spending

$975K

Beneficiaries

3,876

14,814 claims

Per beneficiary

$252

$0.70 per unit

View as table
YearSpending
2020$1,157,073
2021$1,295,086
2022$1,271,668
2023$1,122,751
2024$975,101

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 819 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.